and that older age, presence of glaucoma or diabetes mellitus (DM), larger radiation doses, larger tumor size, lack of rectus muscle disinsertion, and anterior tumor location may be associated with larger IOP elevations.
Results. Of 113 patients identified as having uveal melanoma, 40 were excluded owing to incomplete records. There were 33 men and 40 women. The mean (SD) age was 61.9 (15.7) years. One patient had open-angle glaucoma, no patients had ocular hypertension, and 12 patients had DM.
Three IOP variables were constructed: a preoperative IOP composite for each patient, defined as the average of preoperative IOP measurements (Յ3 measurements); delta IOP (⌬IOP), or the change in IOP as measured on a perioperative day minus the preoperative composite; and the maximum ⌬IOP (⌬IOP max ) for each patient.
The mean preoperative IOP composite was 16.0 mm Hg. This was statistically different from the mean IOP max of 24.3 mm Hg during brachytherapy (P Ͻ.001) but not statistically different from the mean IOP of 15.5 mm Hg 1 day after plaque removal (P = .24) (Figure) . The mean (SD) ⌬IOP max during plaque therapy was 8.5 (6.0) mm Hg. This was not statistically different for tumors at the posterior pole, midperiphery, and ciliary body (P=.15). Using a linear regression model, there was no relationship between tumor height and ⌬IOP max (P=.53) or between the mean total radiation dose and ⌬IOP max (P=.46). There was limited correlation between plaque diameter and ⌬IOP max using a linear regression model (r 2 =0.07; P=.02). The ⌬IOP max for patients with DM was not statistically different from the ⌬IOP max for those without DM (P = .40). Eighteen patients with extraocular muscle disinsertion did not have statistically different ⌬IOP max compared with 55 patients without extraocular muscle disinsertion (P = .72).
Comment. This study demonstrated a statistically significant trend of increased IOP of 8 mm Hg in eyes treated with Collaborative Ocular Melanoma Study-style iodine 125 brachytherapy that persisted while the plaque was in place but resolved by the first postoperative day. Ten patients (14%) experienced IOP increases of 15 mm Hg or more, and 23 (32%) required topical hypotensive therapy. These medications may minimize the IOP elevation associated with brachytherapy. Factors such as age, DM, plaque size or location, tumor height, and radiation dose do not serve as reliable indicators of who will experience these marked elevations in IOP. Given the number experiencing moderate IOP elevation and our inability to identify these patients preoperatively, regular IOP monitoring may be advisable for patients while undergoing iodine 125 brachytherapy. (Figure 1A and B) . Spectraldomain OCT demonstrated widespread outer retinal disruption, the nematode located in the inner retina, and an elevated epiretinal membrane ( Figure 1C and D and Figure 2A) . Photocoagulation of the worm was performed, avoiding the fovea ( Figure 1E ). The patient began treatment with a 30-day course of albendazole, 400 mg/d. Three days later, the worm had moved into the su- perior retina and was still motile. More aggressive photocoagulation was applied and the worm was successfully killed ( Figure 1F) .
The patient reported significant subjective improvement, and his visual acuity measured 20/40 OS 1 month and 20/25 OS 3 months following the initial visit. Spectraldomain OCT showed disruption of the photoreceptors in the papillomacular region secondary to prior photocoagulation but progressive restoration of the normal inner segment/outer segment junction and photoreceptor architecture in the fovea ( Figure 2B and C) .
Comment. Diffuse unilateral subacute neuroretinitis was initially characterized by Gass et al 1 and further described by Gass and Braunstein. 2 Typically, patients initially have unilateral ocular inflammation, optic disc swelling, and chorioretinitis. This condition is caused by at least 2 separate nematodes of different sizes. It has been suggested that the smaller nematode, measuring approximately 500 µm in length, is Ancylostoma caninum and the larger nematode, measuring 1500 to 2000 µm in length, is Baylisascaris procyonis. [2] [3] [4] Progression to optic atrophy, diffuse arteriolar attenuation, pigmentary degeneration, and significant vision loss occur if the nematode is not killed. The size of the nematode in this case is consistent with the larger worm.
Both antiparasitic medication and thermal laser photocoagulation can halt progression and may lead to visual improvement in some patients with diffuse unilateral subacute neuroretinitis. 5, 6 The treatment of choice is photocoagulation if the worm can be identified. At the initial laser treatment, the worm demonstrated rapid movement across the macula, propelling itself with a whipping movement. It was presumed to have been killed when movement ceased. However, 3 days later the worm migrated to the superior retina. At the second photocoagulation, there was minimal movement and more aggressive laser was applied. It is possible that albendazole treatment resulted in impaired motility or that the initial laser injured the nematode.
Spectral-domain OCT demonstrated the initial inner retinal location of the nematode, associated diffuse disruption of the outer retinal architecture, and an elevated epiretinal membrane. Following treatment, progressive restoration of the inner segment/outer segment junction and outer retinal architecture suggests photoreceptor recovery. Persistent optic nerve pallor and visual field loss are likely the result of permanent damage to the ganglion cells, nerve fiber layer, and retinal pigment epithelium. The foveal epiretinal membrane was not seen on subsequent spectral-domain OCT and may have represented an inflammatory change that resolved. These findings coincided with improved visual acuity and support evidence that early killing of the nematode can allow visual improvement correlating with anatomical changes seen on spectral-domain OCT. A, A horizontal section through the fovea at the initial visit shows widespread outer retinal disruption (white arrow) and an elevated epiretinal membrane over the fovea (dark arrow). Images 1 month (B) and 3 months (C) following treatment demonstrate disruption of the photoreceptors in the papillomacular region secondary to prior photocoagulation and progressive restoration of the inner segment/outer segment junction (upper arrow) and photoreceptor architecture (lower arrow) in the fovea.
